Plasma matrix metalloproteinase 7, CC-chemokine ligand 18, and periostin as markers for pulmonary sarcoidosis.


Journal

Respiratory investigation
ISSN: 2212-5353
Titre abrégé: Respir Investig
Pays: Netherlands
ID NLM: 101581124

Informations de publication

Date de publication:
Nov 2020
Historique:
received: 20 05 2020
revised: 03 07 2020
accepted: 12 07 2020
pubmed: 2 9 2020
medline: 26 11 2021
entrez: 2 9 2020
Statut: ppublish

Résumé

Some patients with sarcoidosis experience worsening of pulmonary lesions. However, no biomarker has been identified that reflects pulmonary disease status in sarcoidosis. We investigated the usefulness of potential markers of pulmonary fibrosis in patients with sarcoidosis. Plasma matrix metalloproteinase 7 (MMP-7), CC-chemokine ligand 18 (CCL-18), and periostin levels were evaluated in 60 patients with sarcoidosis and 30 healthy controls; bronchoalveolar lavage fluid levels were analyzed in 22 patients with sarcoidosis. To determine the usefulness of these markers, we explored potential correlations between these markers and sarcoidosis clinical characteristics. Plasma MMP-7, CCL-18, and periostin concentrations were significantly higher in patients with sarcoidosis than those in healthy controls. MMP-7 concentrations in plasma and bronchoalveolar lavage fluid were higher in patients with sarcoidosis with parenchymal infiltration than in those without lung lesions. Moreover, MMP-7 concentration was negatively correlated with pulmonary function. Among these novel biomarkers, MMP-7 most precisely reflected pulmonary sarcoidosis disease status and thus, might be useful for diagnosing and evaluating sarcoidosis, particularly in patients with pulmonary parenchymal lesions.

Sections du résumé

BACKGROUND BACKGROUND
Some patients with sarcoidosis experience worsening of pulmonary lesions. However, no biomarker has been identified that reflects pulmonary disease status in sarcoidosis. We investigated the usefulness of potential markers of pulmonary fibrosis in patients with sarcoidosis.
METHODS METHODS
Plasma matrix metalloproteinase 7 (MMP-7), CC-chemokine ligand 18 (CCL-18), and periostin levels were evaluated in 60 patients with sarcoidosis and 30 healthy controls; bronchoalveolar lavage fluid levels were analyzed in 22 patients with sarcoidosis. To determine the usefulness of these markers, we explored potential correlations between these markers and sarcoidosis clinical characteristics.
RESULTS RESULTS
Plasma MMP-7, CCL-18, and periostin concentrations were significantly higher in patients with sarcoidosis than those in healthy controls. MMP-7 concentrations in plasma and bronchoalveolar lavage fluid were higher in patients with sarcoidosis with parenchymal infiltration than in those without lung lesions. Moreover, MMP-7 concentration was negatively correlated with pulmonary function.
CONCLUSION CONCLUSIONS
Among these novel biomarkers, MMP-7 most precisely reflected pulmonary sarcoidosis disease status and thus, might be useful for diagnosing and evaluating sarcoidosis, particularly in patients with pulmonary parenchymal lesions.

Identifiants

pubmed: 32868264
pii: S2212-5345(20)30114-3
doi: 10.1016/j.resinv.2020.07.003
pii:
doi:

Substances chimiques

Biomarkers 0
CCL18 protein, human 0
Cell Adhesion Molecules 0
Chemokines, CC 0
Ligands 0
POSTN protein, human 0
MMP7 protein, human EC 3.4.24.23
Matrix Metalloproteinase 7 EC 3.4.24.23

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

479-487

Informations de copyright

Copyright © 2020 The Japanese Respiratory Society. Published by Elsevier B.V. All rights reserved.

Déclaration de conflit d'intérêts

Conflict of interest The authors declare no competing interests regarding this research. K.I. received a research grant from Shino-Test Co., Ltd. S.H. received honoraria from Nippon Boehringer Ingelheim Co., Ltd. and research funding from Teijin-Pharma Co., Ltd.

Auteurs

Takuma Isshiki (T)

Department of Respiratory Medicine, Toho University School of Medicine, Tokyo, Japan. Electronic address: takuma.isshiki@med.toho-u.ac.jp.

Hisayo Matsuyama (H)

Department of Respiratory Medicine, Toho University School of Medicine, Tokyo, Japan. Electronic address: hisayo-matsuyama@hotmail.co.jp.

Tetsuo Yamaguchi (T)

Shinjuku Tsurukame Clinic, Tokyo, Japan. Electronic address: yamatet@icloud.com.

Toshisuke Morita (T)

Department of Laboratory Medicine, Toho University School of Medicine, Tokyo, Japan. Electronic address: toshimrt@med.toho-u.ac.jp.

Junya Ono (J)

Shino-test Co. Ltd, Tokyo, Japan. Electronic address: junya.ono@shino-test.co.jp.

Satoshi Nunomura (S)

Division of Medical Biochemistry, Department of Biomolecular Sciences, Saga Medical School, Saga, Japan. Electronic address: nunomura@cc.saga-u.ac.jp.

Kenji Izuhara (K)

Division of Medical Biochemistry, Department of Biomolecular Sciences, Saga Medical School, Saga, Japan. Electronic address: kizuhara@cc.saga-u.ac.jp.

Susumu Sakamoto (S)

Department of Respiratory Medicine, Toho University School of Medicine, Tokyo, Japan. Electronic address: susumu1029@med.toho-u.ac.jp.

Sakae Homma (S)

Department of Advanced and Integrated Interstitial Lung Disease Research, School of Medicine, Toho University, Tokyo, Japan. Electronic address: sahomma@med.toho-u.ac.jp.

Kazuma Kishi (K)

Department of Respiratory Medicine, Toho University School of Medicine, Tokyo, Japan. Electronic address: kazuma.kishi@med.toho-u.ac.jp.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH